APLT insider trading

Applied Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
375
Last 90 days
0
Buys / sells
5% / 44%
Market cap

APLT insider activity at a glance

FilingIQ has scored 375 insider transactions for APLT since May 16, 2019. The most recent filing in our index is dated Feb 3, 2026.

Across the full history, 18 open-market purchases and 164 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on APLT insider trades is 56.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Latest APLT Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

13F funds holding APLT

Frequently asked

How many insider trades does FilingIQ track for APLT?
FilingIQ tracks 375 Form 4 insider transactions for APLT (Applied Therapeutics, Inc.), covering filings from May 16, 2019 onwards. 0 of those were filed in the last 90 days.
Are APLT insiders net buyers or net sellers?
Across the full Form 4 history for APLT, 18 transactions (5%) were open-market purchases and 164 (44%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does APLT insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

Methodology & sources

Every APLT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.